5 Most Undervalued Biotech Stocks To Buy According To Hedge Funds

2. United Therapeutics Corporation (NASDAQ:UTHR)

Number of Hedge Fund Holders: 51

PE Ratio as of February 29: 11.47

United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company that focuses on developing and commercializing products to address unmet medical needs for patients with chronic and life-threatening diseases. On February 21, United Therapeutics Corporation (NASDAQ:UTHR) reported a Q4 GAAP EPS of $4.36 and a revenue of $614.7 million, outperforming Wall Street estimates by $0.17 and $38.83 million, respectively. It is one of the most undervalued stocks to invest in. 

According to Insider Monkey’s fourth quarter database, 51 hedge funds were bullish on United Therapeutics Corporation (NASDAQ:UTHR), compared to 48 funds in the preceding quarter. Kurt Von Emster’s VenBio Select Advisor is the largest stakeholder of the company, with 2.85 million shares worth $628.6 million. 

Follow United Therapeutics Corp (NASDAQ:UTHR)